Bausch (BHC) Down on Q1 Earnings & Sales Miss, View Trimmed
Zacks Investment Research | May 08, 2020 06:43AM ET
Shares of Bausch Health Companies (NYSE:BHC) Inc. industry ’s decline of 3.7%.
The company’s adjusted earnings per share of 89 cents were a penny short of the Zacks Consensus Estimate of 90 cents and down from $1.02 reported in the year-ago quarter.
Total revenues of $2.01 billion missed the Zacks Consensus Estimate by 1.68% and marginally declined from $2.02 billion a year ago. Revenues were negatively impacted by the COVID-19 pandemic to the tune of approximately $35 million.
Quarter in Detail
Revenues in the Bausch + Lomb/International segment (comprised 55.3% of the total revenues) were $1.1 billion, roughly flat year over year. Excluding the impact of discontinuations and divestitures, the segment organically improved approximately 2%, driven by growth in the Global Consumer and International business.
The Salix segment revenues rose 7% year over year to $477 million, primarily driven by 23% growth in Xifaxan.
The company announced top-line results from a phase II study evaluating an investigative soluble solid dispersion (SSD) formulation of immediate release (IR) rifaximin in combination with the current standard-of-care therapy for the treatment of Overt Hepatic Encephalopathy. Results showed that the 40 mg BID of rifaximin SSD IR plus standard-of-care therapy arm met its primary endpoint with statistically significantly superior results compared with the placebo plus standard-of-care therapy arm.
The Ortho Dermatologics segment revenues were $133 million, down 4% year over year due to lower volumes resulting from the loss of exclusivity of Elidel, Zovirax and Solodyn. This was partially offset by 34% growth in the Global Solta business, driven by continued strong demand for ThermageFLX following its launch in the Asia-Pacific region.
Get The News You Want
Diversified Products segment revenues were $288 million, down 9% from the year-ago quarter, primarily due to the loss of exclusivity of certain products.
During the quarter, the company repaid debt by approximately $220 million with cash generated from operations.
2020 Guidance Lowered
The company lowered its revenue guidance range for 2020 primarily due to the actual and anticipated impacts of the COVID-19 pandemic. Revenues are now projected to be $7.80-$8.20 billion compared with the previous guidance of $8.65-$8.85 billion.
Our Take
Bausch missed on earnings and sales in the first quarter as the COVID-19 pandemic wreaks havoc worldwide. The company also lowered its annual guidance amid the uncertainty. Postponement of elective medical procedures until the situation stabilizes will continue to affect the surgical business.
Nevertheless, the Salix business continues to grow as Xifaxan maintains momentum. The company has resolved the outstanding Xifaxan IP litigation with Sandoz, the generic unit of Novartis NVS . The company now holds market exclusivity for the drug until 2028.
Meanwhile, Bausch initiated a clinical study on Virazole (ribavirin for inhalation solution, USP) in combination with standard-of-care therapy to treat hospitalized adult patients having respiratory distress due to the deadly coronavirus in Canada.
We note that Mallinckrodt (NYSE:MNK) ENDP withdrew its guidance due to the uncertain environment.
Bausch currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft (NASDAQ:MSFT) in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.